Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04015518
Registration number
NCT04015518
Ethics application status
Date submitted
9/07/2019
Date registered
11/07/2019
Date last updated
28/07/2022
Titles & IDs
Public title
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
Query!
Scientific title
Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIb Dose-finding Study to Evaluate Safety and Efficacy of Different Subcutaneous Doses of BI 655130 in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP)
Query!
Secondary ID [1]
0
0
2018-003078-28
Query!
Secondary ID [2]
0
0
1368-0016
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Palmoplantar Pustulosis (PPP)
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Spesolimab
Treatment: Drugs - Placebo
Treatment: Drugs - Spesolimab
Treatment: Drugs - Spesolimab
Treatment: Drugs - Spesolimab
Treatment: Drugs - Spesolimab
Other: Placebo & Spesolimab - Subcutaneous injections of placebo matching Spesolimab, with subcutaneous injections of Spesolimab starting at week 16, for a total treatment time of 52 weeks.
Experimental: Spesolimab 'Speso Low' - Subcutaneous injections of Spesolimab in a low dose scheme for a total treatment time of 52 weeks.
Experimental: Spesolimab 'Speso Medium-low' - Subcutaneous injections of Spesolimab in a medium-low dose scheme for a total treatment time of 52 weeks.
Experimental: Spesolimab 'Speso Medium-high' - Subcutaneous injections of Spesolimab in a medium-high dose scheme for a total treatment time of 52 weeks.
Experimental: Spesolimab 'Speso High' - Subcutaneous injections of Spesolimab in a high dose scheme for a total treatment time of 52 weeks.
Treatment: Drugs: Spesolimab
Subcutaneous injections of Spesolimab starting at week 16, for a total treatment time until week 52.
Treatment: Drugs: Placebo
Subcutaneous injections of placebo matching Spesolimab from week 0 to 16.
Treatment: Drugs: Spesolimab
Subcutaneous injections of Spesolimab in a low dose scheme for a total treatment time of 52 weeks.
Treatment: Drugs: Spesolimab
Subcutaneous injections of Spesolimab in a medium-low dose scheme for a total treatment time of 52 weeks.
Treatment: Drugs: Spesolimab
Subcutaneous injections of Spesolimab in a medium-high dose scheme for a total treatment time of 52 weeks.
Treatment: Drugs: Spesolimab
Subcutaneous injections of Spesolimab in a high dose scheme for a total treatment time of 52 weeks.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPP ASI) at Week 16 From Baseline
Query!
Assessment method [1]
0
0
The percentage change in PPP ASI at Week 16 from baseline. The PPP ASI is a tool that provides a numeric scoring for patients overall PPP disease state, ranging from 0 (best) to 72 (worst). It is a linear combination of the percent of surface area of skin that is affected on the palms and soles of the body and the severity of erythema, pustules, and scaling (desquamation): The percent change from baseline is calculated as (PPP ASI current - PPP ASI baseline) / PPP ASI baseline * 100%.
Least square (LS) means, differences and confidence intervals were estimated by (Restricted maximum likelihood)-based Mixed effect model for repeated measurements (MMRM) including the fixed, categorical effects of treatment at each visit, region and the continuous effect of baseline at each visit as well as random effects of subject. Values post rescue medication or 6 weeks following last study treatment before discontinuation were censored. Unstructured covariance matrix was used.
Query!
Timepoint [1]
0
0
week 0 (baseline) and week 16
Query!
Secondary outcome [1]
0
0
Change From Baseline in Palmoplantar Pustulosis Pain Visual Analogue Scale (VAS) Score at Week 4
Query!
Assessment method [1]
0
0
Change from baseline in Palmoplantar Pustulosis Pain Visual Analogue Scale (VAS) score at Week 4. The PPP Pain VAS is a unidimensional measure of pain intensity due to palmoplantar pustulosis on palms and/or soles. It is a continuous scale comprised of a horizontal or vertical line, 10 centimeters (cm) in length, anchored by word descriptors at each end (score ranges from "no pain" at 0 cm to "very severe pain" at 10 cm). The patient was asked to place a vertical ( | ) mark on the horizontal line to indicate the severity of the pain.
Least square (LS) means, differences and confidence intervals were estimated by (Restricted maximum likelihood)-based MMRM including the fixed, categorical effects of treatment at each visit, region and the continuous effect of baseline at each visit as well as random effects of subject. Values post rescue medication or 6 weeks following last study treatment before discontinuation were censored. Unstructured covariance matrix was used.
Query!
Timepoint [1]
0
0
week 0 (baseline) and week 4.
Query!
Secondary outcome [2]
0
0
Change From Baseline in Palmoplantar Pustulosis Pain Visual Analogue Scale (VAS) Score at Week 16
Query!
Assessment method [2]
0
0
Change from baseline in Palmoplantar Pustulosis Pain Visual Analogue Scale (VAS) score at Week 16. The PPP Pain VAS is a unidimensional measure of pain intensity due to palmoplantar pustulosis on palms and/or soles. It is a continuous scale comprised of a horizontal or vertical line, 10 centimeters (cm) in length, anchored by word descriptors at each end (score ranges from "no pain" at 0 cm to "very severe pain" at 10 cm). The patient was asked to place a vertical ( | ) mark on the horizontal line to indicate the severity of the pain.
Least square (LS) means, differences and confidence intervals were estimated by (Restricted maximum likelihood)-based MMRM including the fixed, categorical effects of treatment at each visit, region and the continuous effect of baseline at each visit as well as random effects of subject. Values post rescue medication or 6 weeks following last study treatment before discontinuation were censored. Unstructured covariance matrix was used.
Query!
Timepoint [2]
0
0
week 0 (baseline) and week 16.
Query!
Secondary outcome [3]
0
0
Palmoplantar Pustulosis Severity Index (PPP SI) Change From Baseline at Week 16
Query!
Assessment method [3]
0
0
PPP SI change from baseline at Week 16. The PPP SI is based on the severity score of individual components (erythema, pustules, and scaling/desquamation) of PPP ASI assessments. The most severely affected area based on pustules was identified by the investigator at baseline and assessed at all subsequent visits. The PPP SI was calculated by summing up the individual components of PPP ASI assessment (range 0 (best) to 12 (worst)) at each visit for the identified location.
Least square (LS) means, differences and confidence intervals were estimated by (Restricted maximum likelihood)-based Mixed effect model for repeated measurements (MMRM) including the fixed, categorical effects of treatment at each visit, region and the continuous effect of baseline at each visit as well as random effects of subject. Values post rescue medication or 6 weeks following last study treatment before discontinuation were censored. Unstructured covariance matrix was used.
Query!
Timepoint [3]
0
0
week 0 (baseline) and week 16.
Query!
Secondary outcome [4]
0
0
Number of Patients Achieving a 50% Decrease From Baseline in Palmoplantar Pustulosis Area and Severity Index Score at Week 16 (PPP ASI50)
Query!
Assessment method [4]
0
0
Number of patients achieving a 50% decrease from baseline in Palmoplantar Pustulosis Area and Severity Index score at week 16 (PPP ASI50). The PPP ASI is an investigator assessment of the extent and severity of palmoplantar pustulosis lesions on the palms and soles in PPP patients. This tool provides a numeric scoring for patients overall PPP disease state, ranging from 0 (best) to 72 (worst). It is a linear combination of the percent of surface area of skin that is affected on the palms and soles of the body and the severity of erythema, pustules, and scaling (desquamation). When (PPP ASI baseline - PPP ASI current)/ PPP ASI baseline * 100% >= 50%, PPP ASI50 = 1.
Query!
Timepoint [4]
0
0
week 0 (baseline) and week 16
Query!
Secondary outcome [5]
0
0
Number of Patients Achieving a 75% Decrease From Baseline in Palmoplantar Pustulosis Area and Severity Index Score at Week 16 (PPP ASI75)
Query!
Assessment method [5]
0
0
Number of patients achieving a 75% decrease from baseline in Palmoplantar Pustulosis Area and Severity Index score at week 16 (PPP ASI75). The PPP ASI is an investigator assessment of the extent and severity of palmoplantar pustulosis lesions on the palms and soles in PPP patients. This tool provides a numeric scoring for patients overall PPP disease state, ranging from 0 (best) to 72 (worst). It is a linear combination of the percent of surface area of skin that is affected on the palms and soles of the body and the severity of erythema, pustules, and scaling (desquamation). When (PPP ASI baseline - PPP ASI current)/ PPP ASI baseline * 100% >= 75%, PPP ASI75 = 1.
Query!
Timepoint [5]
0
0
week 0 (baseline) and week 16
Query!
Secondary outcome [6]
0
0
Number of Patients With Palmoplantar Pustulosis Physician Global Assessment (PPP PGA) Clear/Almost Clear (0 or 1) at Week 16
Query!
Assessment method [6]
0
0
Number of patients with Palmoplantar Pustulosis Physician Global Assessment (PPP PGA) clear/almost clear (0 or 1) at Week 16. The PPP PGA relies on investigator assessment of the patient's skin presentation on the palms and soles. The investigator scored the individual components (erythema, pustules, and scaling/crusting) from 0 (best) to 4 (worst) as clear, almost clear, mild, moderate or severe. PPP PGA categorization is based on the mean of the four individual components.
Query!
Timepoint [6]
0
0
week 0 (baseline) and week 16
Query!
Secondary outcome [7]
0
0
Number of Patients With Palmoplantar Pustulosis Physician Global Assessment (PPP PGA) Pustules Clear/Almost Clear (0 or 1) at Week 16
Query!
Assessment method [7]
0
0
Number of patients with Palmoplantar Pustulosis Physician Global Assessment (PPP PGA) pustules clear/almost clear (0 or 1) at Week 16. The PPP PGA relies on investigator assessment of the patient's skin presentation on the palms and soles. The investigator scored the pustules from 0 (best) to 4 (worst) as clear, almost clear, mild, moderate or severe.
Query!
Timepoint [7]
0
0
week 0 (baseline) and week 16
Query!
Secondary outcome [8]
0
0
The Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPP ASI) at Week 52 From Baseline
Query!
Assessment method [8]
0
0
The percentage change in PPP ASI at Week 52 from baseline. The PPP ASI is an investigator assessment of the extent and severity of palmoplantar pustulosis lesions on the palms and soles in PPP patients. This tool provides a numeric scoring for patients overall PPP disease state, ranging from 0 (best) to 72 (worst). It is a linear combination of the percent of surface area of skin that is affected on the palms and soles of the body and the severity of erythema, pustules, and scaling (desquamation).
LS means, differences and confidence intervals were estimated by (Restricted maximum likelihood)-based MMRM including the fixed, categorical effects of treatment at each visit, region and the continuous effect of baseline at each visit as well as random effects of subject. Values post rescue medication or 6 weeks following last study treatment before discontinuation were censored. Unstructured covariance matrix was used.
Query!
Timepoint [8]
0
0
week 0 (baseline) and week 52
Query!
Eligibility
Key inclusion criteria
- 18 to 75 years of legal age (according to local legislation) at screening.
- Diagnosis of Palmoplantar Pustulosis defined as presence of primary, persistent (>3
months duration), sterile, macroscopically visible pustules on the palms and/or soles,
without or with plaque psoriasis elsewhere on the body.
- PPP PGA of at least moderate severity (=3) at screening and baseline.
- A minimum PPP ASI score of 12 at screening and baseline.
- Male or female patients. Women of childbearing potential (WOCBP) must be ready and
able to use highly effective methods of birth control per ICH M3 (R2).
- Signed and dated written informed consent in accordance with ICH GCP and local
legislation prior to admission to the trial.
- Further criteria apply.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
- Severe, progressive, or uncontrolled condition such as renal, hepatic, haematological,
endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease, or signs
and symptoms thereof.
- Presence or known history of anti-TNF-induced PPP-like disease.
- Patient with a transplanted organ (with exception of a corneal transplant >12 weeks
Prior to screening) or who have ever received stem cell therapy (e.g., Prochymal).
- Known history of lymphoproliferative disease, including lymphoma, or signs and
symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy
and/or splenomegaly.
- Further criteria apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
31/07/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
28/07/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
152
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Woden Dermatology - Phillip
Query!
Recruitment hospital [2]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [3]
0
0
Veracity Clinical Research - Wooloongabba
Query!
Recruitment hospital [4]
0
0
Skin Health Institute Inc - Carlton
Query!
Recruitment hospital [5]
0
0
Royal Melbourne Hospital - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2606 - Phillip
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
4102 - Wooloongabba
Query!
Recruitment postcode(s) [4]
0
0
3053 - Carlton
Query!
Recruitment postcode(s) [5]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Kansas
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Missouri
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Nebraska
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New Jersey
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Utah
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Virginia
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Bruxelles
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Leuven
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Alberta
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
New Brunswick
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Ontario
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Quebec
Query!
Country [18]
0
0
Czechia
Query!
State/province [18]
0
0
Pardubice
Query!
Country [19]
0
0
Czechia
Query!
State/province [19]
0
0
Prague 3
Query!
Country [20]
0
0
Czechia
Query!
State/province [20]
0
0
Prague
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Nice
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Paris
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Toulouse
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Berlin
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Erlangen
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Frankfurt am Main
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Heidelberg
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Kiel
Query!
Country [29]
0
0
Hungary
Query!
State/province [29]
0
0
Miskolc
Query!
Country [30]
0
0
Hungary
Query!
State/province [30]
0
0
Pecs
Query!
Country [31]
0
0
Hungary
Query!
State/province [31]
0
0
Szombathely
Query!
Country [32]
0
0
Hungary
Query!
State/province [32]
0
0
Veszprem
Query!
Country [33]
0
0
Japan
Query!
State/province [33]
0
0
Aichi, Nagoya
Query!
Country [34]
0
0
Japan
Query!
State/province [34]
0
0
Aichi, Toyoake
Query!
Country [35]
0
0
Japan
Query!
State/province [35]
0
0
Chiba, Ichikawa
Query!
Country [36]
0
0
Japan
Query!
State/province [36]
0
0
Ehime, Toon
Query!
Country [37]
0
0
Japan
Query!
State/province [37]
0
0
Fukuoka, Fukuoka
Query!
Country [38]
0
0
Japan
Query!
State/province [38]
0
0
Gifu, Gifu
Query!
Country [39]
0
0
Japan
Query!
State/province [39]
0
0
Hokkaido, Asahikawa
Query!
Country [40]
0
0
Japan
Query!
State/province [40]
0
0
Hokkaido, Obihiro
Query!
Country [41]
0
0
Japan
Query!
State/province [41]
0
0
Hokkaido, Sapporo
Query!
Country [42]
0
0
Japan
Query!
State/province [42]
0
0
Kagawa, Takamatsu
Query!
Country [43]
0
0
Japan
Query!
State/province [43]
0
0
Kanagawa, Sagamihara
Query!
Country [44]
0
0
Japan
Query!
State/province [44]
0
0
Kumamoto, Kumamoto
Query!
Country [45]
0
0
Japan
Query!
State/province [45]
0
0
Kyoto, Kyoto
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Miyagi, Sendai
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Nagano, Matsumoto
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Okayama, Okayama
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Okinawa, Nakagami-gun
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Osaka, Osaka-sayama
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Osaka, Osaka
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Osaka, Suita
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Shiga, Otsu
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Tochigi, Shimotsuke
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Tokyo, Itabashi-ku
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Tokyo, Shinjuku-ku
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Tokyo, Shinjuku
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Toyama, Takaoka
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Wakayama, Wakayama
Query!
Country [60]
0
0
Korea, Republic of
Query!
State/province [60]
0
0
Incheon
Query!
Country [61]
0
0
Korea, Republic of
Query!
State/province [61]
0
0
Seongnam
Query!
Country [62]
0
0
Korea, Republic of
Query!
State/province [62]
0
0
Seoul
Query!
Country [63]
0
0
Netherlands
Query!
State/province [63]
0
0
Breda
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Krakow
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Lodz
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Lublin
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Olsztyn
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Wroclaw
Query!
Country [69]
0
0
Russian Federation
Query!
State/province [69]
0
0
Chelyabinsk
Query!
Country [70]
0
0
Russian Federation
Query!
State/province [70]
0
0
Kazan
Query!
Country [71]
0
0
Russian Federation
Query!
State/province [71]
0
0
Saint-Petersburg
Query!
Country [72]
0
0
Taiwan
Query!
State/province [72]
0
0
Taipei
Query!
Country [73]
0
0
United Kingdom
Query!
State/province [73]
0
0
Exeter
Query!
Country [74]
0
0
United Kingdom
Query!
State/province [74]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective is to provide dose-ranging data for 4 dose regimens of BI 655130
compared to placebo on the primary endpoint of percentage change from baseline in PPP ASI at
Week 16. The target dose(s) will be estimated from the model by incorporating information on
the minimum clinically relevant effect and accounting for safety.
Supportive dose-ranging assessments will also be done on pre-specified secondary endpoints.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04015518
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04015518
Download to PDF